Late Breaking Abstract - IMPACT study — single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs — UK

Abstract

Introduction: The objective of this study was to evaluate differences in healthcare resource utilization (HRU) and costs in the UK between fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), FF/VI, and UMEC/VI, among patients with symptomatic COPD and a history of exacerbations, using data from IMPACT (NCT02164513). Methods: This study is a post-hoc analysis of COPD-related HRU data collected in the 52-week study during the on-treatment period, which included unscheduled visits to a physician office/clinic, urgent care/outpatient center, emergency department, home care, hospital days (general ward and intensive care unit (ICU)), and rescue medication use. Rates of HRU for the intent to treat population were annualized based on per patient rates and the mean number of treatment exposure days. UK-specific unit costs were applied to the HRU rates to generate cost estimates (2018, GBP). Results: Over 52 weeks the mean (SD) number of exposure days were 325.9 (94.9) for FF/UMEC/VI (n=4151), 304.5 (116.2) for FF/VI (n=4134), and 298.7 (120.8) for UMEC/VI (n=2070). The largest differences in HRU were for hospital days, with FF/UMEC/VI (1.26 general ward, 0.16 ICU) and FF/VI (1.28, 0.14) having lower rates than UMEC/VI (1.54, 0.23). Annualized drug costs for FF/UMEC/VI were higher (FF/UMEC/VI=£637, FF/VI=£308, UMEC/VI=£434), but costs for other HRU were lower (£841, £846, £1,075), with total costs of £1,478, £1,153, and £1,509. Incremental total costs for FF/UMEC/VI were £325 versus FF/VI, and -£31 versus UMEC/VI. Conclusions: Treatment with FF/UMEC/VI resulted in similar HRU versus FF/VI and lower HRU and total costs compared with UMEC/VI.